Treatment of Deep Vein Thrombosis in Lymphoma Patients

Initial Treatment Approach

The American Society of Clinical Oncology recommends low-molecular-weight heparin (LMWH) as the preferred treatment for deep vein thrombosis in patients with lymphoma, with options including dalteparin 200 U/kg once daily, tinzaparin 175 U/kg once daily, and enoxaparin 1 mg/kg twice daily 1
For patients with severe renal impairment, unfractionated heparin (UFH) is preferred due to its shorter half-life and reversibility with protamine sulfate 1
Fondaparinux is a reasonable alternative for patients with a history of heparin-induced thrombocytopenia (HIT) 1

LMWH should be continued for at least 6 months as monotherapy without transitioning to warfarin, with a 49% relative risk reduction in recurrent VTE demonstrated in the CLOT study with dalteparin compared to vitamin K antagonists in cancer patients 1, 3, 4
Specific dosing for extended therapy includes dalteparin 200 IU/kg once daily for 1 month followed by 150 IU/kg once daily for 5 months 4

The minimum treatment duration is 6 months for cancer-associated DVT, with extended anticoagulation beyond 6 months recommended for patients with active lymphoma, those receiving ongoing chemotherapy, and patients with metastatic disease 4, 5

If LMWH is not available or feasible, vitamin K antagonists (VKAs) with a target INR of 2-3 are acceptable alternatives 1, 3
Inferior vena cava filters should only be used in patients with contraindications to anticoagulation or recurrent VTE despite adequate anticoagulation with LMWH 5, 6

Regular monitoring of platelet counts is recommended to detect heparin-induced thrombocytopenia, though this is rare with LMWH 4
For patients with primary CNS lymphoma, anticoagulation should still be used for established DVT, but with careful monitoring to limit hemorrhagic complications 5